Argenomics – Alberto Saul, President – Argentina
The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several…
Bioceres is an Argentina-based firm that manages investments in agricultural biotechnology and related sciences. It was founded in December 2001 by 23 farmers and is now owned by more than 270 shareholders, most of them innovative farmers but also coops and different actors from the agro-industrial sector. Every year, Bioceres shareholders plant about 2.5 million hectares in different regions of Latin America.
Since its beginnings, Bioceres has been a bridge between the scientific community and the agricultural production sector, fostering public-private associations and the development of collaborative networks.
Bioceres is a firm open to new shareholders with a shared dream-developing new technologies that help us use natural resources in a more efficient way while increasing and stabilizing the productivity of ecosystems.
Bioceres goes from genes to seeds, linking the laboratory to the field, adding value in every stage, and building and strengthening public-private partnerships.
CONTACT DETAILS
Ocampo 210 bis, predio CCT Rosario, (2000) Rosario, Santa Fe, Argentina
Phone: (54) 341 486 1100 Fax:(54) 341 486 1100
The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several…
The general manager of Ferring Argentina believes that the country has one of the strongest social security systems in Latin America, with high reimbursement levels and coverage for most chronic…
The general manager of Roche Argentina weighs up the factors that have allowed the country to be included among the top three performing markets in the region for Roche, and…
The general manager of Gennoma Laboratorios Argentina weighs up the factors of why raising brand awareness using public television is the key success to his company communication strategy. When…
“In the last decade, as a result of high and sustained growth, the Argentine pharmaceutical industry increased production by more than 240 percent, which speaks volumes about the capacity of…
The country president of AstraZeneca Argentina discusses the country’s patent laws, the work being done to bring innovation back to Argentina, and the challenge of a strong branded generics market…
When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a…
Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura…
The executive management of Nycomed said in an interview that ‘the tremendous growth of the pharmaceutical industry will not occur in either Europe or the United States, but in emerging…
Could you give us an overview of the generics sector in Argentina as it stands at the moment? The generics market in Argentina was started immediately after the regulation regarding…
Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on…
What have been the recent major milestones for Richmond? One of the milestones for Laboratorios Richmond was to have developed the first branded oncological generic in the world. For Laboratorios…
See our Cookie Privacy Policy Here
